Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis.
head and neck squamous cell carcinoma
immune microenvironment
prognosis
treatment
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
01
2021
accepted:
15
04
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
We aimed to review the literature on the tumor microenvironment as a key player in tumor growth and anti-cancer treatment responses in head and neck cancer. We reviewed the recent literature on this topic, using the following research words: "tumor microenvironment" and "head and neck cancer or neoplasm or head and neck squamous cell carcinoma" and "immune cells" and "stromal cells". A search was conducted on the PubMed website and reports from international meetings, presentations and abstracts. The tumor microenvironment is a complex network in which myeloid cells, tumoral cells, growth factors and cytokines are involved in angiogenesis, the extracellular matrix and epithelial-to-mesenchymal transition. Immune resistance and rapid tumor growth depend on immunosuppressive and pro-tumoral environments. Further investigations to classify and adequately treat patients with head and neck cancer are required.
Identifiants
pubmed: 34040438
doi: 10.2147/CMAR.S277907
pii: 277907
pmc: PMC8139676
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3973-3980Informations de copyright
© 2021 Denaro et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Oncology. 2012;83(2):108-16
pubmed: 22777379
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cancer Res. 2020 Oct 1;80(19):4185-4198
pubmed: 32816856
Front Immunol. 2018 Feb 23;9:353
pubmed: 29527212
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14
pubmed: 21282607
J Immunother Cancer. 2018 Sep 12;6(1):88
pubmed: 30208943
JAMA Oncol. 2018 Nov 1;4(11):1583-1588
pubmed: 29931076
Cancers (Basel). 2020 Dec 17;12(12):
pubmed: 33348579
Oncotarget. 2015 Dec 8;6(39):42067-80
pubmed: 26573233
Trends Pharmacol Sci. 2019 Jan;40(1):4-7
pubmed: 30527590
ESMO Open. 2018 Jan 9;3(1):e000257
pubmed: 29344407
Oncotarget. 2020 Mar 24;11(12):1037-1050
pubmed: 32256977
J Clin Oncol. 2019 Dec 1;37(34):3266-3274
pubmed: 31618129
J Control Release. 2021 Mar 10;331:321-334
pubmed: 33434599
Oncotarget. 2018 Oct 5;9(78):34708-34718
pubmed: 30410671
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cytokine Growth Factor Rev. 2006 Jun;17(3):141-6
pubmed: 16540364
J Natl Cancer Inst. 1998 Apr 15;90(8):587-96
pubmed: 9554441
J Natl Cancer Inst. 2019 Mar 1;111(3):233-244
pubmed: 30615137
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Cancer Lett. 2021 Apr 1;502:84-96
pubmed: 33450360
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
Curr Oncol Rep. 2020 Jun 29;22(8):81
pubmed: 32602047
Front Cell Dev Biol. 2020 Dec 17;8:580005
pubmed: 33392181
Ann Oncol. 2019 Jan 1;30(1):68-75
pubmed: 30407504
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Eur J Oral Sci. 2017 Aug;125(4):247-257
pubmed: 28653423
Cancer Immunol Immunother. 2017 Dec;66(12):1619-1629
pubmed: 28856441
Cancer Cell Int. 2020 Jan 17;20:22
pubmed: 31988638
Cancer Res. 2008 Jun 1;68(11):4331-9
pubmed: 18519693
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Cancers (Basel). 2020 Nov 15;12(11):
pubmed: 33203092
Anticancer Res. 2007 Mar-Apr;27(2):817-24
pubmed: 17465207
Oncogene. 2020 Feb;39(8):1784-1796
pubmed: 31740787
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Cancer Sci. 2018 Jan;109(1):54-64
pubmed: 29034589
ESMO Open. 2019 Jul 16;4(Suppl 2):e000542
pubmed: 31555490
Front Immunol. 2015 May 26;6:263
pubmed: 26074923
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Head Neck Oncol. 2013 Feb 27;5(3):24
pubmed: 24723971
Front Genet. 2019 Dec 04;10:1252
pubmed: 31921296
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Anticancer Res. 2006 Nov-Dec;26(6B):4409-13
pubmed: 17201162
Front Oncol. 2019 Nov 12;9:1212
pubmed: 31781506